This register continues to churn just as it was below 3c.
The DSA agreement should bear fruits imminently. A few contracts and endorsements from a few institutions before the EOY should light up the stock as they set up offices in Europe.
FDA approval is the wildcard, ePat have submitted and since this is a Class 1 device approval could come well before Q2 next year.
EPAT General Discussion, page-815
Add PCK (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.3¢ |
Change
-0.001(2.94%) |
Mkt cap ! $53.98M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.4¢ | 3.3¢ | $14.20K | 429.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 563128 | 3.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.4¢ | 264400 | 2 |
View Market Depth
| Last trade - 12.07pm 20/08/2024 (20 minute delay) ? |
| PCK (ASX) Chart |